This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
MorphoSys Beheer
Beheer criteriumcontroles 1/4
We currently do not have sufficient information about the CEO.
Belangrijke informatie
Arkadius Pichota
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | less than a year |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | less than a year |
Gemiddelde ambtstermijn bestuur | 6.5yrs |
Recente managementupdates
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11CEO
Arkadius Pichota
less than a year
Tenure
Mr. Arkadius Pichota, Ph D., MBA., is Chief Executive Officer of MorphoSys AG from June 2024. Mr. Pichota served as President, General Manager and Chairman of the Board of the Novartis subsidiary Navigate...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chief Legal and Human Resources Officer & Member of Management Board | 4.6yrs | €1.10m | 0.0036% $ 99.7k | |
Chief Executive Officer | less than a year | geen gegevens | geen gegevens | |
Chief Financial Officer | less than a year | geen gegevens | geen gegevens | |
Chief Research & Development Officer | 1.8yrs | geen gegevens | geen gegevens | |
Head of Accounting & Tax | no data | geen gegevens | geen gegevens | |
Head of Discovery Alliances & Technologies | no data | geen gegevens | geen gegevens | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Chief Business Officer | no data | geen gegevens | geen gegevens | |
Head of Technical Operations | no data | geen gegevens | geen gegevens | |
Head of Alliance Management | no data | geen gegevens | geen gegevens | |
Head of Clinical Operations | no data | geen gegevens | geen gegevens | |
Head of Business Team | no data | geen gegevens | geen gegevens |
1.0yrs
Gemiddelde duur
Ervaren management: MOR's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Member of Scientific Advisory Board | 7.9yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 7.9yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 7.9yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 7.9yrs | geen gegevens | geen gegevens | |
Independent Member of Supervisory Board | 5.2yrs | €92.60k | geen gegevens | |
Chairman of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
Member of the Supervisory Board | less than a year | geen gegevens | geen gegevens | |
Deputy Chairman of the Supervisory Board | less than a year | geen gegevens | geen gegevens |
6.5yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren bestuur: MOR's board of directors are considered experienced (6.5 years average tenure).